Thursday, May 12, 2022

Slaoui apologizes ‘unreservedly’ after sexual harassment allegations prompt biotechs to part ways


No deflecting, no denying. Moncef Slaoui, M.D., issued an open apology around the sexual harassment allegation that led GlaxoSmithKline to cut ties on Wednesday. But the biopharma world isn’t in a forgiving mood right now.

“I would like to apologize unreservedly to the employee concerned and I am deeply sorry for any distress caused,” Slaoui said in a statement Wednesday.

The former GSK vaccine exec and head of Operation Warp Speed said he’ll “work hard to redeem” himself with those affected, but for now he’ll hunker down by stepping away from his current positions in the industry to focus on family.

The apology came after GSK booted him from chairmanship at GSK-controlled Galvani Bioelectronics over allegations of harassment and inappropriate behavior by an employee that happened years ago, when he was with GSK. The British drugmaker said an investigation into Slaoui’s conduct had substantiated the claims.

Whatever his own decisions, GSK’s damning accusation Wednesday leaves little room for Slaoui’s career in today’s biopharma indutstry. Newly launched mega-biotech Centessa Pharmaceuticals immediately parted ways with him, merely a month after tapping him as chief scientific officer.

RELATED: GSK cuts ties with Slaoui over sexual harassment allegations as CEO Walmsley vows to rename R&D site

Centessa’s management and board “were troubled to learn of yesterday’s news regarding Dr. Slaoui,” Centessa CEO Saurabh Saha, M.D., Ph.D., said in a statement Thursday. “Centessa is absolutely committed to fostering a culture of respect that is free from harassment and discrimination of any kind.”

Centessa was founded by life sciences venture capital bigwig Medicxi, where Slaoui has been a partner since September 2017. As of Thursday morning, Saloui’s intro can still be seen on Medicxi’s website, and the company didn’t immediately reply to a request for comment. By way of the European investment shop, Slaoui also holds board positions at other Medicxi portfolio companies such as U.K. biotech Divide & Conquer.

RELATED: Warp Speed chief Slaoui resigns at Biden’s request as COVID-19 shots are unleashed: report

U.S. vaccine developer Vaxcyte said Thursday that Slaoui has stepped down as its chairman. Medixci also participated in the company’s previous funding round when the firm was known as SutroVax.



Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...